heart failure
Conditions
Brief summary
The primary endpoint is the composite of (repeated) HF hospitalizations, (repeated) urgent HF hospital visits and cardiovascular death.
Detailed description
All-cause mortality, Cardiovascular death., (Repeated) HF hospitalization, (repeated) urgent HF hospital visits, Cost-effectiveness., All-cause hospitalizations., Unscheduled cardiovascular hospital visits., Days alive out of hospital., Quality of Life., Heart rate in both AF and sinus rhythm., To assess side effects (including SUSARs) associated with study medication., Initiation of (recurrence of) AF in patients with sinus rhythm at baseline., Conversion to sinus rhythm and maintenance of sinus rhythm in patients with AF at baseline, Proteomics and validating hits in elisa's
Interventions
DRUGDIGOXIN
Sponsors
Universitair Medisch Centrum Groningen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the composite of (repeated) HF hospitalizations, (repeated) urgent HF hospital visits and cardiovascular death. | — |
Secondary
| Measure | Time frame |
|---|---|
| All-cause mortality, Cardiovascular death., (Repeated) HF hospitalization, (repeated) urgent HF hospital visits, Cost-effectiveness., All-cause hospitalizations., Unscheduled cardiovascular hospital visits., Days alive out of hospital., Quality of Life., Heart rate in both AF and sinus rhythm., To assess side effects (including SUSARs) associated with study medication., Initiation of (recurrence of) AF in patients with sinus rhythm at baseline., Conversion to sinus rhythm and maintenance of sinus rhythm in patients with AF at baseline, Proteomics and validating hits in elisa's | — |
Countries
Netherlands
Outcome results
None listed